Nasus Pharma Ltd
About Nasus Pharma Ltd
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.2B
- Net income
- -$5.9M
- Total assets
- $5.0M
- Market cap
- $34.3M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $34.3M
- Shares outstanding
- 11.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 13, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $5.9M in FY2025.
- Trading 68% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Nasus Pharma Ltd.
Write a review
News about Nasus Pharma Ltd
News & sentiment via Polygon.io
